Data Entry Maintenance

Metadata Commons Identifier

HMC000052

Project Title

Clinical Implementation of Diagnostic Biomarker Assays in Heart and Kidney Transplantation

Project Description

<p><span style="color: rgb(38, 38, 38); font-family: system-ui, -apple-system, 'system-ui', 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Fira Sans', 'Droid Sans', 'Helvetica Neue', sans-serif; font-size: 14px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">Transplantation is the best treatment for many patients with kidney failure.However, transplant rejection is a serious complication that reduces graft andpatient survival, and decreases the health and other benefits of this treatment.The lack of simple tests to predict or diagnose rejection remains a major problem in the management of transplant recipients. Tissue biopsies remain the best test currently available, but are invasive, expensive, and have some risk to the patient.</span><br style="box-sizing: border-box; outline-color: var(--ut-focus-outline-color,-webkit-focus-ring-color); clear: both; color: rgb(38, 38, 38); font-family: system-ui, -apple-system, 'system-ui', 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Fira Sans', 'Droid Sans', 'Helvetica Neue', sans-serif; font-size: 14px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"><span style="color: rgb(38, 38, 38); font-family: system-ui, -apple-system, 'system-ui', 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Fira Sans', 'Droid Sans', 'Helvetica Neue', sans-serif; font-size: 14px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">The objectives of this study were to: 1) Externally qualify genomic and proteomic biomarker panels of rejection discovered in the 1st phase of this study (BiT1); 2) Perform additional microarray, proteomics, and metabolomic assays to further refine the biomarker panels as needed for specificity and sensitivity requirements; and 3) Establish clinically relevant assays for gene and protein biomarkers that have been discovered in the Vancouver cohorts.</span></p>

Project Funder(s)

Genome British Columbia, Genome Canada, Mitacs, PROOF Centre of Excellence, Canada Foundation for Innovation

Project Institution(s)

University of British Columbia, PROOF Centre of Excellence

Project Investigator(s)

Bruce McManus, Raymond Ng, Paul Keown, W Robert McMaster

Data Access Request URL*

Keywords

heart transplantation, kidney transplantation, proteomics, transcriptomics, acute rejection, diagnosis, prognosis, biomarkers

Publication Link

https://pubmed.ncbi.nlm.nih.gov/32553820/

Study Completed

Cohort Name

Biomarkers in Transplantation 2 (BiT2)

Cohort Size

692

Disease/Condition Studied

kidney transplant, heart transplant, end-stage organ failure

Enrollment Time Window

2009-2014

Biobanking Consent Available

Medical History Available

Ethnicity Availability

Time Course

Patient Phenotypes

no acute rejection, mild acute rejection, severe acute rejection, no chronic rejection, chronic rejection

Patient Outcomes

mortality, infections

Clinical Data Types Available

biopsy results, demographics, lab results, medication, viral infections, vital signs

Time Course Data Points

pre-transplant, weeks 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, and 12, and months 6, 12, 18 and 24 post-transplant

Enrollment City

Groups

Project

Cohort

Enrollment City

Groups

Samples and Omics